203 related articles for article (PubMed ID: 31190122)
1. Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease.
Geng S; Kuang Z; Peissig PL; Page D; Maursetter L; Hansen KE
Osteoporos Int; 2019 Oct; 30(10):2019-2025. PubMed ID: 31190122
[TBL] [Abstract][Full Text] [Related]
2. Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease.
Seiler-Mussler S; Limbach AS; Emrich IE; Pickering JW; Roth HJ; Fliser D; Heine GH
Clin J Am Soc Nephrol; 2018 Apr; 13(4):569-576. PubMed ID: 29507005
[TBL] [Abstract][Full Text] [Related]
3. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3.
Shardlow A; McIntyre NJ; Fluck RJ; McIntyre CW; Taal MW
BMJ Open; 2017 Aug; 7(8):e016528. PubMed ID: 28838895
[TBL] [Abstract][Full Text] [Related]
4. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
[TBL] [Abstract][Full Text] [Related]
5. Association of renal function with bone mineral density and fracture risk in the Longitudinal Aging Study Amsterdam.
Chen H; Lips P; Vervloet MG; van Schoor NM; de Jongh RT
Osteoporos Int; 2018 Sep; 29(9):2129-2138. PubMed ID: 29947873
[TBL] [Abstract][Full Text] [Related]
6. Prospective cohort study: Cinacalcet-mediated lowering of PTH level and cardiovascular disease mortality in younger Korean patients with stage 5 CKD at a Korean secondary hospital.
Sin HY
J Clin Pharm Ther; 2017 Oct; 42(5):607-614. PubMed ID: 28585333
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
9. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
Ennis JL; Worcester EM; Coe FL; Sprague SM
J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
[TBL] [Abstract][Full Text] [Related]
10. Parathyroid hormone may be an early predictor of low serum hemoglobin concentration in patients with not advanced stages of chronic kidney disease.
Russo D; Morrone L; Di Iorio B; Andreucci M; De Gregorio MG; Errichiello C; Russo L; Locatelli F
J Nephrol; 2015 Dec; 28(6):701-8. PubMed ID: 25113067
[TBL] [Abstract][Full Text] [Related]
11. Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
Phelps KR; Stote KS; Mason D
Clin Nephrol; 2014 Sep; 82(3):191-201. PubMed ID: 25079864
[TBL] [Abstract][Full Text] [Related]
12. How Well Does Renal Transplantation Cure Hyperparathyroidism?
Lou I; Foley D; Odorico SK; Leverson G; Schneider DF; Sippel R; Chen H
Ann Surg; 2015 Oct; 262(4):653-9. PubMed ID: 26366545
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Intact PTH and Bio-Intact PTH Assays Among Non-Dialysis Dependent Chronic Kidney Disease Patients.
Einbinder Y; Benchetrit S; Golan E; Zitman-Gal T
Ann Lab Med; 2017 Sep; 37(5):381-387. PubMed ID: 28643486
[TBL] [Abstract][Full Text] [Related]
14. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?
Anderson JL; Vanwoerkom RC; Horne BD; Bair TL; May HT; Lappé DL; Muhlestein JB
Am Heart J; 2011 Aug; 162(2):331-339.e2. PubMed ID: 21835295
[TBL] [Abstract][Full Text] [Related]
15. Secondary hyperparathyroidism is associated with pulmonary hypertension in older patients with chronic kidney disease and proteinuria.
Genctoy G; Arikan S; Gedik O
Int Urol Nephrol; 2015 Feb; 47(2):353-8. PubMed ID: 25537827
[TBL] [Abstract][Full Text] [Related]
16. Elderly patients with chronic kidney disease have higher risk of hyperparathyroidism.
Elias RM; Moysés RMA
Int Urol Nephrol; 2017 Oct; 49(10):1815-1821. PubMed ID: 28695313
[TBL] [Abstract][Full Text] [Related]
17. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis.
Danese MD; Kim J; Doan QV; Dylan M; Griffiths R; Chertow GM
Am J Kidney Dis; 2006 Jan; 47(1):149-56. PubMed ID: 16377396
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study.
Hsu S; Bansal N; Denburg M; Ginsberg C; Hoofnagle AN; Isakova T; Ix JH; Robinson-Cohen C; Wolf M; Kestenbaum BR; de Boer IH; Zelnick LR
J Bone Miner Res; 2024 May; 39(4):433-442. PubMed ID: 38477777
[TBL] [Abstract][Full Text] [Related]
19. Value of Intraoperative Parathyroid Hormone Assay during Parathyroidectomy in Dialysis and Renal Transplant Patients with Secondary and Tertiary Hyperparathyroidism.
El-Husseini A; Wang K; Edon A; Saxon D; Lima F; Sloan D; Sawaya BP
Nephron; 2018; 138(2):119-128. PubMed ID: 29131092
[TBL] [Abstract][Full Text] [Related]
20. The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease.
Whitlock RH; Leslie WD; Shaw J; Rigatto C; Thorlacius L; Komenda P; Collister D; Kanis JA; Tangri N
Kidney Int; 2019 Feb; 95(2):447-454. PubMed ID: 30579724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
